We showed that orally administered montelukast suppressed the formation and progression of AAA, decreased the degradation of the medial elastin area, regulated the expression of inflammatory proteins in the aortic wall, and inhibited MMP-2 activity. Here, ELN is linked to triple-A syndrome.